Literature DB >> 8482467

Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.

H T Lynch1, T C Smyrk, P Watson, S J Lanspa, J F Lynch, P M Lynch, R J Cavalieri, C R Boland.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) dates to Warthin's description of family G, which he began studying in 1895. Warthin's observations were not fully appreciated until 1966 when two families with an autosomal dominant inheritance pattern of nonpolyposis colorectal cancer (CRC) and endometrial cancer were described. This condition was first termed the "cancer family syndrome" and was later renamed HNPCC. Some have proposed that HNPCC consists of at least two syndromes: Lynch syndrome I, with hereditary predisposition for CRC having early (approximately 44 years) age of onset, a proclivity (70%) for the proximal colon, and an excess of synchronous and metachronous colonic cancers and Lynch syndrome II, featuring a similar colonic phenotype accompanied by a high risk for carcinoma of the endometrium. Transitional cell carcinoma of the ureter and renal pelvis and carcinomas of the stomach, small bowel, ovary, and pancreas also afflict some families. Current estimates indicate that HNPCC may account for as much as 6% of the total CRC burden. There are no known premonitory phenotypic signs or biomarkers of cancer susceptibility in the Lynch syndromes. This report will summarize current knowledge, with emphasis on the manner in which this knowledge can be employed effectively for diagnosis and management of HNPCC.

Entities:  

Mesh:

Year:  1993        PMID: 8482467     DOI: 10.1016/0016-5085(93)90368-m

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  169 in total

1.  An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1.

Authors:  P Hutter; J Wijnen; C Rey-Berthod; I Thiffault; P Verkuijlen; D Farber; N Hamel; B Bapat; S N Thibodeau; J Burn; J Wu; E MacNamara; K Heinimann; G Chong; W D Foulkes
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

Review 2.  [Carcinogenesis and hereditart colon cancers].

Authors:  F Kullmann
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

Review 3.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 4.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 5.  Molecular basis for subdividing hereditary colon cancer?

Authors:  W M Grady
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

6.  Clement Richard Boland, Jr., MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Clement Richard Boland
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

7.  The mechanism of microsatellite instability is different in synchronous and metachronous colorectal cancer.

Authors:  Fernando S Velayos; Suk-Hwan Lee; Hongming Qiu; Sharon Dykes; Raymond Yiu; Jonathan P Terdiman; Julio Garcia-Aguilar
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

8.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome.

Authors:  Lucía Pérez-Cabornero; Mar Infante; Eladio Velasco; Enrique Lastra; Cristina Miner; Mercedes Durán
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

10.  Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.

Authors:  Patrick Chun; Zev A Wainberg
Journal:  Gastrointest Cancer Res       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.